Onco Actu du 5 juillet 2018

Pour info : Onco Actu interrompt sa parution pendant deux semaines. 

Rendez-vous le 23 juillet !

	4.2 Dép., diag. & prono. - Génome
As the NHS celebrates 70 years Genomics England sequences its 70,000th genome [Genomics England] This milestone comes just five months after the 100,000 Genomes Project reached its halfway point – signalling that it is well on track to reach its goal of 100,000 genomes by the end of this year.
	4.7 Dép., diag. & prono. - Col de l'utérus
HPV testing could be more accurate than smear tests for initial screening of cervical cancer [NHS Choices] While the results of the study are encouraging and suggest that HPV testing could work well as a primary test in place of cervical smears, we do not have longer-term results to show whether it actually makes a difference to how many women get invasive cervical cancer or die of the disease.
	5. Traitements
Pancreatic Cancer Study Suggests Potential of Molecularly Tailored Treatments [Genome Web] The relatively small number of subjects in the matched treatment cohort points to another challenge. Of the 640 patients for whom Perthera generated a report, follow-up information was not available for 200; 111 passed away before starting new treatment; 173 remained on the treatment they were using prior to receiving their report; and 156 began a new treatment regimen. Of the 156 who started a new treatment, 126 chose a treatment presented by the report. Of those 126, 35 had highly actionable alterations.
	5.10 Traitements - Essais
Getting results: why NHS clinical trials are the envy of the world [The Guardian] From cancer to dementia, UK patients are benefiting from a democratised system of research.
UK's top surgeon calls for new procedures to undergo clinical trials [The Guardian] “If you go into a cancer clinic you’d expect a significant number of patients to be in some sort of study,” he said. “In a surgical clinic it’s less than 1%. There’s a whole structural healthcare environment that’s not really fit for purpose.”
	5.12.5 Immunothérapies - Pharma
Compugen Announces FDA Clearance of IND Application for COM701, a First-in-Class Immuno-Oncology Therapeutic Antibody [Compugen] A Phase 1 trial in patients with advanced solid tumors is to be conducted at multiple centers in the United States.
Compugen Advancing Cancer Immunotherapies to Clinical Trials [GEN News] Compugen today said clinical trials will be launched for a pair of its cancer immunotherapy candidates targeting advanced solid tumors—its lead immuno-oncology program targeting PVRIG, which had been in clinical hold since April, and another program targeting the ILDR2, or immunoglobulin-like domain-containing receptor 2, protein whose development will be overseen by Bayer.
	5.12.8 Immunothérapies - Economie
Final NICE no for BMS’ Opdivo in urothelial carcinoma [PharmaTimes] The cost regulator noted that Opdivo has not been directly compared with other treatments, and so it is not clear how effective it is compared with current clinical practice.
	5.2 Pharma
Exelixis Announces CELESTIAL Phase 3 Pivotal Trial Results Published in The New England Journal of Medicine [Exelixis] Trial results formed the basis of regulatory filings in the U.S. and European Union for CABOMETYX® (cabozantinib) for previously treated advanced hepatocellular carcinoma.
Data show Imnovid-based triple therapy PFS benefit in blood cancer [PharmaTimes] According to results of the Phase III OPTIMISMM trial, adding Imnovid (pomalidomide) to Velcade (bortezomib) and low-dose dexamethasone significantly extended PFS to 11.2 months compared to 7.10 months for those taking the latter two alone, equating to a reduction in the risk of disease progression or death by 39 percent.
	5.3.4 Traitements - AMM (FDA, EMA,...)
EMA Recommends Extension of Indications for Lenvatinib [ESMO] New indication concerns first-line treatment of advanced or unresectable hepatocellular carcinoma.
	5.4 Traitements - Economie
Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer [NICE] More evidence on niraparib is being collected, until 2020. After this NICE will decide whether or not to recommend it for use on the NHS and update the guidance. It will be available through the Cancer Drugs Fund until then.